60
Participants
Start Date
June 28, 2019
Primary Completion Date
November 1, 2023
Study Completion Date
January 1, 2024
Vancomycin plus VE416 before PNOIT
Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks followed by PNOIT
Vancomycin plus VE416 with PNOIT
Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT
Placebo plus VE416 with PNOIT
Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT
Placebo plus placebo with PNOIT
Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by placebo for VE416 PO QD x 6 weeks with concomitant PNOIT
RECRUITING
Massachusetts General Hospital, Boston
Vedanta Biosciences, Inc.
INDUSTRY
Massachusetts General Hospital
OTHER